RT Journal Article
T1 Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository.
A1 de Azevedo Lopes, Erivelton
A1 Balbi, Gustavo Guimarães Moreira
A1 Tektonidou, Maria G
A1 Pengo, Vittorio
A1 Sciascia, Savino
A1 Ugarte, Amaia
A1 Belmont, H Michael
A1 Gerosa, Maria
A1 Fortin, Paul R
A1 Lopez-Pedrera, Chary
A1 Ji, Lanlan
A1 Cohen, Hannah
A1 de Jesús, Guilherme Ramires
A1 Branch, D Ware
A1 Nalli, Cecilia
A1 Petri, Michelle
A1 Rodriguez, Esther
A1 Kello, Nina
A1 Ríos-Garcés, Roberto
A1 Knight, Jason S
A1 Atsumi, Tatsuya
A1 Willis, Rohan
A1 Bertolaccini, Maria Laura
A1 Erkan, Doruk
A1 Andrade, Danieli
A1 APS ACTION, 
K1 Anti-beta-2 glycoprotein I antibodies
K1 Anticardiolipin antibodies
K1 Antiphospholipid antibodies
K1 Antiphospholipid syndrome
K1 Lupus Anticoagulant
K1 Primary antiphospholipid syndrome
AB Antiphospholipid syndrome (APS) is characterized by episodes of thrombosis, obstetric morbidity or both, associated with persistently positive antiphospholipid antibodies (aPL). Studying the profile of a rare disease in an admixed population is important as it can provide new insights for understanding an autoimmune disease. In this sense of miscegenation, Brazil is characterized by one of the most heterogeneous populations in the world, which is the result of five centuries of interethnic crosses of people from three continents. The objective of this study was to compare the clinical and laboratory characteristics of Brazilian vs. non-Brazilian primary antiphospholipid syndrome (PAPS) patients. We classified PAPS patients into 2 groups: Brazilian PAPS patients (BPAPS) and PAPS patients from other countries (non-BPAPS). They were compared regarding demographic characteristics, criteria and non-criteria APS manifestations, antiphospholipid antibody (aPL) profile, and the adjusted Global Antiphospholipid Syndrome Score (aGAPSS). We included 415 PAPS patients (88 [21%] BPAPS and 327 [79%] non-BPAPS). Brazilian patients were significantly younger, more frequently female, sedentary, obese, non-white, and had a higher frequency of livedo (25% vs. 10%, p  Our study suggests a specific profile of PAPS in Brazil with higher frequency of selected non-criteria manifestations and lupus anticoagulant positivity. Lupus anticoagulant (not triple positivity) was the major aPL predictor of a classification criteria event.
YR 2021
FD 2021-10-28
LK https://hdl.handle.net/10668/25857
UL https://hdl.handle.net/10668/25857
LA en
DS RISalud
RD Apr 7, 2025